PARTNERSHIPS | One key factor for the success of this venture is the ability to screen and identify promising projects within the academic / early-stage ecosystem which are ripe for translational development and well-suited to value generation. Such projects will offer the potential of breakthrough therapeutic products capable of transforming treatment options for patients. MedXCell has developed positive relationships with institutions and individual researchers both to access current research results and to inspire new projects. MedXCell has already successfully collaborated with the SATT AxLR (Montpellier’s academic institutions Tech Transfer office on which MedXCell disposes of a right of first refusal) and Federal Institute of Technology in Lausanne (EPFL), Switzerland.

There is a gap at the academic / industrial interface that academic research and big pharma cannot fill because of their mutual inability to operate effectively in the translational phase of these projects. The co-designing phase is crucial so that researchers engage with industry executives that understand the needs and dynamics of translational technology and innovation development and who can plan and implement the metamorphosis of breakthrough ideas into viable breakthrough product concepts, with effective understanding and management of the attrition rate at this stage.


The Montpellier Hospitals have a history spanning 1’000 years. It was in the 20th century that close collaboration between universities and hospitals culminated in the creation of the University Hospital Centers (CHUs) in France. The fundamental missions of the University Hospital Center of Montpellier today are care, teaching, and research.  It is organized around 13 university hospital centers grouping all medical and surgical specialties and spread over several geographical sites in Montpellier.


Located at, and operating in close collaboration the CHU of Montpellier is the Institute of Regenerative Medicine and Biotherapies (IRMB), which is dedicated to research on adult and embryonic stem cells, including both basic biological aspects and innovative applications of regenerative therapy. On a single site, fundamental research, hospital laboratories and private companies are gathered around common technical platforms and infrastructures in health biology dedicated to stem cells.


The University of Montpellier (UM) is the 6th largest university in France, with about 50,000 students. One of the most innovative higher education institutions in the world, UM was credited as the most innovative French university in 2018 Reuter’s ranking. The University of Montpellier provides World-Class research teams with state-of-the-art equipment and shared technological platforms.


EPFL is Europe’s most cosmopolitan technical university. It welcomes students, professors and collaborators of more than 120 nationalities. EPFL has both a Swiss and international vocation and focuses on three missions: teaching, research and innovation.  EPFL collaborates with an important network of partners, including other universities and colleges, secondary schools, industry and the economy, political circles and the general public, with the aim of having a real impact on society.


Cambridge Innovation Center in Massachusetts is a global leader in building and operating innovation communities. The MedXCell Group has chosen CIC to be its base for North America.